Neumedicines Inc. is a privately held, clinical stage, biotechnology company developing protein therapeutics that address unmet clinical and societal needs in Oncology, Infectious Disease, Hematology and Immunology. The company operates from its headquarters and laboratories in Pasadena, California.
NM-IL-12 (aka HemaMax™, recombinant human interleukin-12 or rHuIL-12), the company’s lead product in development, targets multiple pathways of innate and adaptive immunity, as well as hematopoiesis, is being developed to address a broad range of clinical indications.
To date, Neumedicines has secured $64 million from BARDA to develop HemaMax™ for the treatment of the Hematopoietic Syndrome of Acute Radiation Syndrome HSARS and is completing Phase 2 studies for this emergency indication. We have also received $1.5 million from NIH to support a clinical Phase 2a study in study CTCL , and $2.5 million from the US Army to study surgical/wound infections and to conduct a randomized Phase 2 randomized study in patients undergoing ostomy takedown.
We are currently seeking funding to advance Phase 2b studies in CTCL and DLBCL.
At Neumedicines, we are committed to maximizing the scientific, clinical, and commercial potential of our product pipeline.